The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller

FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller

June 8, 2016 • By Natalie Grover & Toni Clarke

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—A U.S. Food and Drug Administration (FDA) advisory panel recommended approving Teva Pharmaceuticals Industries Ltd’s long-acting opioid painkiller, Vantrela ER, saying data showed it reduces pain and has some abuse-resistant properties.

You Might Also Like
  • U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • Bowing to Pressure, FDA to Reform Painkiller Approval Process

The drug is designed for use every 12 hours for the management of pain severe enough to require around-the-clock treatment in patients who have not derived enough benefit from other treatments.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The panel recommended 14-3 that the drug be approved and largely supported the claim that the painkiller likely deters abuse if swallowed, snorted or injected.

However, most members noted the drug’s abuse-deterrent properties were relatively small, but agreed that there was a place for incremental improvements over existing painkillers.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The committee’s belief is that the data presented for all three of these routes of administration do show at least a modicum of abuse deterrence,” Dr. Raeford Brown Jr., the panel’s chair, says summarizing its views.

The FDA is not obliged to follow the advice of its expert panels but typically does so.

A preliminary FDA review issued on Friday concluded Vantrela ER had abuse-deterrent properties if snorted or injected, but the abuse-deterrent benefit was less clear when the product was swallowed.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The abuse of opioids—a class of drugs that includes heroin and prescription painkillers—has reached epidemic proportions in the U.S. The Centers for Disease Control and Prevention (CDC) estimates that 78 Americans die every day from opioid overdose.

Last week officials in Minnesota determined that death in April of musician Prince was due to an accidental overdose of the synthetic opioid fentanyl. Teva’s drug contains an abuse-resistant form of the commonly used opioid hydrocodone.

Analysts at Mizuho Securities USA estimate Vantrela ER could generate annual sales of $130 million by 2020. The drug would compete with Purdue Pharma LP’s once-daily Hysingla ER and Pernix Therapeutics LLC’s Zohydro ER.

On Wednesday, the panel will discuss Pfizer Inc’s experimental long-acting opioid painkiller, whose proposed trade name is Troxyca ER.

Filed Under: Analgesics, Drug Updates Tagged With: Chronic pain, FDA, Food and Drug Administration, Opioids, Teva Pharmaceuticals

You Might Also Like:
  • U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • Bowing to Pressure, FDA to Reform Painkiller Approval Process
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.